Targeting protein folding in N‐Myc‐driven medulloblastoma

Selective targeting of N‐Myc‐driven Sonic hedgehog (SHH) medulloblastoma has been a challenge for many years and, despite decades of research, few targeted therapy opportunities exist. Recently, Kuzuoglu‐Ozturk et al. characterized the translatome of N‐Myc‐driven medulloblastoma as a promising thera...

Full description

Saved in:
Bibliographic Details
Published inMolecular oncology Vol. 17; no. 3; pp. 387 - 389
Main Authors Valinciute, Gintvile, Roussel, Martine F.
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.03.2023
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Selective targeting of N‐Myc‐driven Sonic hedgehog (SHH) medulloblastoma has been a challenge for many years and, despite decades of research, few targeted therapy opportunities exist. Recently, Kuzuoglu‐Ozturk et al. characterized the translatome of N‐Myc‐driven medulloblastoma as a promising therapeutic target. The study showed that N‐Myc controls a subset of members of the protein folding machinery that could be inhibited pharmacologically and validated a subset of Hsp70 functions as required for medulloblastoma progression in vitro and in vivo. A new study by Kuzuoglu‐Ozturk et al. identified a novel therapeutic vulnerability in N‐Myc‐driven Sonic hedgehog medulloblastoma. Selective translation of protein homeostasis pathways, including protein folding machinery components, drives tumour cell response to proteotoxic stress. Targeting the Hsp70 co‐chaperone leaves cells vulnerable to the proteotoxic stress induced by N‐Myc overexpression and inhibits N‐Myc‐driven medulloblastoma proliferation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1574-7891
1878-0261
DOI:10.1002/1878-0261.13395